抗CD20モノクローナル抗体(mAb)の世界市場2019-2023

◆英語タイトル:Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31859
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年8月28日
◆ページ数:133
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、抗CD20モノクローナル抗体(mAb)の世界市場について調べ、抗CD20モノクローナル抗体(mAb)の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、抗CD20モノクローナル抗体(mAb)の市場規模をセグメンテーション別(製品別(腫瘍学、神経学、免疫学)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は抗CD20モノクローナル抗体(mAb)の世界市場規模が2019-2023期間中に年平均9%成長すると予測しています。
・サマリー
・レポートの範囲
・抗CD20モノクローナル抗体(mAb)の市場状況
・抗CD20モノクローナル抗体(mAb)の市場規模
・抗CD20モノクローナル抗体(mAb)の市場予測
・抗CD20モノクローナル抗体(mAb)の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(腫瘍学、神経学、免疫学)
・抗CD20モノクローナル抗体(mAb)の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Anti-CD20 Monoclonal Antibodies (mABs) Market: About this market
Technavio’s anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. Our analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, our global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.

Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview

High target affinity and specificity of anti-CD20 mABs
Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.

Development of CD20 bispecific antibodies
The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global anti-CD20 monoclonal antibodies (mABs) market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.

Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Oncology – Market size and forecast 2018-2023
• Neurology – Market size and forecast 2018-2023
• Immunology – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing awareness about therapeutic areas
• Presence of reimbursement and patient assistance programs
• Development of CD20 bispecific antibodies
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen Inc.
• Celltrion Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Oncology – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Approved mABs for cancer indications
Exhibit 22: Oncology – Year-over-year growth 2019-2023 (%)
Exhibit 23: Neurology – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Neurology – Year-over-year growth 2019-2023 (%)
Exhibit 25: Immunology – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Immunology – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Some of the approved anti-CD20 mABs in US
Exhibit 33: North America – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Some of the approved anti-CD20 mABs in Europe
Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Some of the major combination therapies for anti-CD20 mABs
Exhibit 48: Serious side effects of anti-CD20 mABs
Exhibit 49: Effect on RITUXAN sales after the launch of biosimilars
Exhibit 50: Some of the recently approved rituximab biosimilars
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Some of the CD20 bispecific antibodies under development
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Vendors covered
Exhibit 56: Vendor classification
Exhibit 57: Market positioning of vendors
Exhibit 58: Amgen Inc. – Vendor overview
Exhibit 59: Amgen Inc. – Organizational developments
Exhibit 60: Amgen Inc. – Geographic focus
Exhibit 61: Amgen Inc. – Key offerings
Exhibit 62: Amgen Inc. – Key customers
Exhibit 63: Celltrion Inc. – Vendor overview
Exhibit 64: Celltrion Inc. – Product segments
Exhibit 65: Celltrion Inc. – Organizational developments
Exhibit 66: Celltrion Inc. – Geographic focus
Exhibit 67: Celltrion Inc. – Segment focus
Exhibit 68: Celltrion Inc. – Key offerings
Exhibit 69: Celltrion Inc. – Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 77: Novartis AG – Vendor overview
Exhibit 78: Novartis AG – Business segments
Exhibit 79: Novartis AG – Organizational developments
Exhibit 80: Novartis AG – Geographic focus
Exhibit 81: Novartis AG – Segment focus
Exhibit 82: Novartis AG – Key offerings
Exhibit 83: Novartis AG – Key customers
Exhibit 84: Pfizer Inc. – Vendor overview
Exhibit 85: Pfizer Inc. – Business segments
Exhibit 86: Pfizer Inc. – Organizational developments
Exhibit 87: Pfizer Inc. – Geographic focus
Exhibit 88: Pfizer Inc. – Segment focus
Exhibit 89: Pfizer Inc. – Key offerings
Exhibit 90: Pfizer Inc. – Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Definition of market positioning of vendors



【掲載企業】

Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗CD20モノクローナル抗体(mAb)の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆